中国肺癌杂志2017，Vol.20Issue(12)：852-856,5.DOI:10.3779/j.issn.1009-3419.2017.12.10
非小细胞肺癌分子靶向EGFR-TKI治疗敏感性与治疗耐受性预测筛选的分子显像研究现状及进展
Current Status and Progress in Molecular Imaging of Non-small Cell Lung Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and Treatment Tolerance Prediction
摘要
Abstract
More than 80％ of lung cancer is non-small cell lung cancer (NSCLC),and the epidermal growth factor receptor (EGFR)-mediated signaling pathway is closely related to the occurrence and development of NSCLC.Small molecule EGFR-tyrosine kinase inhibitors (EGFR-TKI) targeting EGFR have been used in the clinical treatment of NSCLC,and positron emission tomography/computed tomgraphy (PET/CT) imaging can noninvasively monitor the expression and mutation status of EGFR in patients with NSCLC.18F-FDG PET/CT imaging has predictive value for the activation of EGFR mutation and EGFR-TKI treatment efficacy,and in vivo can be directly observed drugs and systemic tumor targeting EGFR combined with the specific circumstances,by PET/CT imaging before and after treatment,to achieve dynamic monitoring,guide the therapy before treatment and treatment of sensitive population screening process,to achieve NSCLC EGFR-TKI precise treatment is essential.关键词
肺肿瘤/EGFR/靶向治疗/PET/CT/分子显像Key words
Lung neoplasms/EGFR/Targeted therapy/PET/CT/Molecular imaging引用本文复制引用
戴东,徐文贵,王琦,李小凤,朱研佳..非小细胞肺癌分子靶向EGFR-TKI治疗敏感性与治疗耐受性预测筛选的分子显像研究现状及进展[J].中国肺癌杂志,2017,20(12):852-856,5.基金项目
本文受天津市自然科学基金(No.17JCYBJC25100)和天津医科大学肿瘤医院人才启动基金(No.B1605)资助 This paper was supported by the grants from Tianjin Natural Science Foundation (No.17JCYBJC25100) and Tianjin Medical University Cancer Institute and Hospital Talent Startup Foundation(No.B1605) (Both to Dong DAI). （No.17JCYBJC25100）
